gsk201505116k1.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending May 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 
 
 
 
GlaxoSmithKline plc
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
I give below details of changes in interests in the Ordinary shares of GlaxoSmithKline plc in respect of the under-mentioned Executive Director on 8 May 2015:
 
 
 
GSK Deferred Annual Bonus Plan
 
S Dingemans
 
 
 
Exercise of a nil priced option over 34,220 shares and 4,620 shares granted on 9 March 2012, both of which vested on 9 March 2015 under the GlaxoSmithKline Deferred Annual Bonus Plan. GlaxoSmithKline delivered the net of tax value in shares being 20,585.
 
The fair market value of an Ordinary Share at the point of exercise on 8 May 2015 was £14.72.
 
The Company and the above-mentioned Executive Director were advised of this transaction on 11 May 2015.
 
This notification relates to a transaction notified in accordance with paragraph 3.1.4R(1)(a) of the Disclosure and Transparency Rules.
 
 
V A Whyte
Company Secretary
 
11 May 2015
 
 

 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: May 11, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc